We searched MEDLINE (Ovid) weekly from 29 September to 26 October 2020 using the same search strategy as described in the original review (1). We did not limit the search by language. This search update yielded 64 results (de-duplicated), and after an independent dual-review process, we identified 15 new studies meeting our inclusion criteria—12 observational studies and 3 systematic reviews with meta-analyses
New Evidence
Findings from 1 new observational study found no evidence of an association with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) use and risk for coronavirus disease 2019 (COVID-19) (2). Findings from an additional 11 new observational studies did not demonstrate an association between use of ACEIs or ARBs and worse outcomes in COVID-19 (3–13). These findings are supported by 3 new systematic reviews with meta-analyses (14–16).Overall, inclusion of 15 studies from this search update does not change the certainty of evidence rating we reported in the original manuscript for key questions 1 or 2. Studies have not examined the benefits and harms of initiating ACEIs or ARBs (that is, new users) in COVID-19 treatment; therefore, evidence for key question 3 remains unclear.